Recent News

Pam Bondi’s compelled testimony over Epstein files turns transparency into a simple power question: who gets protected when the records matter?

Anthropic’s new valuation shows that the AI contest is becoming a contest over compute, capital, and who can afford the next infrastructure bill.

AP reports the Trump administration told prosecutors to avoid pursuing investigations into Venezuela’s acting president as Washington seeks stability and investment access.

FDA advisers backed updating Covid shots for the XFG variant while warning that shrinking surveillance data is making annual vaccine decisions harder to trust.

A Pentagon letter says adversaries are exploiting commercial location data to target U.S. personnel, turning the adtech economy into a national-security risk.

CVS Caremark is bringing Lilly Zepbound back as a preferred covered option, a reminder that drug access often turns on rebate negotiations rather than patient need alone.

A new look at China AI buildout shows why the next phase of artificial intelligence may be decided by power grids as much as by chips.

The Trump administration is reportedly weighing funding for U.S. drone firms, turning autonomous warfare into another test of incentives, favoritism, and public risk.

The Supreme Court’s refusal to take Meta’s appeal lets Vermont test whether Instagram’s engagement model can be treated as a consumer-protection problem.

The FDA’s approval of AbbVie’s rare blood-cancer drug is a reminder that speed, risk and public trust now collide inside every accelerated medical pathway.